🚨 NEWS 🚨

U.S. FDA grants Breakthrough Therapy Designation for ziftomenib, a novel therapy that targets the menin-KMT2A/MLL protein-protein interaction, for the treatment of NPM1-mutated AML.

Read more here 👉 loom.ly/Ff8Eh8g

#AMLsm #leusm #leukemia #MedicalEducation

Dr. Othman Akhtar MCW Cancer Center Clarifying best #autoHCT conditioning for older #PCNSL patients #lymsm #bmtsm #EBMT24 The EBMT

Always a pleasure to hear from Mohamad Mohty, who shared some insights into the treatment & management of steroid-refractory #GvHD & updates on the management of VOD!

#EBMT24 has been filled with some wonderful content & we're excited to share these interviews!

The EBMT #BMTsm

I am honored to serve as editor-in-chief of Blood Global Hematology from ASH, an open-access journal that will serve as a new forum for investigators worldwide and hematology research with a global impact. Georgia Cancer Center

Great to see this out in print in Blood Advances ! 🎉🥳

Check out our study examining the clinical impact of the new European Hematology Association The EBMT grading of immune effector cell-associated hematotoxicity in a cohort of ~550 CAR T cell patients ⤵️

ashpublications.org/bloodadvances/…

Efficacy of autologous and allogeneic hematopoietic cell transplantation in APL: systemic review and meta-analysis
sciencedirect.com/science/articl…
A big shout out to Razan Mohty for leading this effort! Congratulation to all co-authors at Mayo Clinic, Florida.

Highlights:
10% of pts

Another #CART approval: Liso-cel for #CLL FDA Oncology

“CAR-T Therapy for CLL: What is the supporting evidence so far?” A comprehensive review published in Clin Hematol Int. Official journal of ⁦IACH⁩
⁦CLL Advocates Network⁩ ⁦Razan Mohty⁩ ⁦Mohamed Kharfan-Dabaja, MD, MBA⁩ ⁦HealthTree for CLL⁩ ⁦ELLyE l’Association #Lymphomes #LLC chi.scholasticahq.com/article/88382-…

Finally out!
Happy to share our study on HHV6 reactivation after haploidentical HCT.
Our findings endorse the safety of combining ATG and PTCy. The main risk factor for HHV6 reactivation was a low lymphocyte count at day 30 after HCT.

ARTICLE👉chi.scholasticahq.com/article/92525 Mohamad Mohty

1/2 At #TANDEM24 , Rawan Faramand, MD, joined us to discuss an oral presentation on real-world outcomes for AYA patients with relapsed/refractory b-cell ALL receiving CD19-directed CAR T cell therapy. More on the abstract ➡️ bit.ly/42JRUk8 #MoffittTANDEM24

Outstanding presentation by Julio Chavez providing an update of the #ELARA study at #ASTCT 2024

ASTCT celebrates the work of Dr. Bipin Savani with the Survivorship SIG Lifetime Achievement Award! Thank you for your mentorship and everything you have done for the field!
#tandem24

Congratulations, Dr Bipin Savani 🎉 Very well-deserved. Thank you for your invaluable mentorship and unwavering support. Your dedication to the field is truly inspiring. Wishing you continued success and many more achievements ahead! 🌟 #Tandem24

Very well deserved👏🏻👏🏻👏🏻